乌司奴单抗与维得利珠单抗治疗持续性优于抗TNF药物:PANIC研究
基于澳大利亚全国医保数据的回顾性队列研究,纳入2499例IBD患者(8219人年随访),比较生物制剂治疗持续性。克罗恩病中乌司奴单抗持续性优于抗TNF药物(HR 1.79,95%CI 1.32-2.38,P<0.01);中重度溃疡性结肠炎中维得利珠单抗优于抗TNF药物(HR 1.67,95%CI 1.27-2.18,P<0.001)。一线治疗及抗TNF药物联用免疫调节剂可提高持续性。
要点
- 一线治疗持续性优于非一线治疗;抗TNF药物联用硫唑嘌呤或甲氨蝶呤可提高持续性。
核心结论
- 克罗恩病中乌司奴单抗治疗持续性最高,中重度溃疡性结肠炎中维得利珠单抗持续性最高。
- 一线治疗和抗TNF药物联用免疫调节剂是提高生物制剂持续性的因素。
研究设计与样本
- 回顾性全国人群队列研究,基于澳大利亚药品福利计划数据,纳入2499例克罗恩病或溃疡性结肠炎患者,共8219人年随访。
- 采用Kaplan-Meier分析和Cox比例风险模型评估阿达木单抗、英夫利西单抗、维得利珠单抗和乌司奴单抗的治疗持续性。
主要发现
- 非抗TNF治疗联用免疫调节剂未显著提高持续性(P>0.05);硫唑嘌呤提高抗TNF药物在克罗恩病(P<0.001)和溃疡性结肠炎(P=0.03)中的持续性;甲氨蝶呤仅提高抗TNF药物在克罗恩病中的持续性(P=0.001)。
- 一线治疗持续性优于非一线治疗(P<0.001);肛瘘型克罗恩病中英夫利西单抗与阿达木单抗持续性无显著差异(P=0.11)。
临床怎么用
- 克罗恩病可优先考虑乌司奴单抗以提高治疗持续性,中重度溃疡性结肠炎可优先考虑维得利珠单抗。
- 抗TNF药物治疗时联用硫唑嘌呤(克罗恩病和溃疡性结肠炎)或甲氨蝶呤(仅克罗恩病)可能改善持续性。
- 生物制剂应尽早作为一线治疗使用,以获得更好的持续性。
局限性
- 回顾性研究设计,基于医保理赔数据,可能存在未控制的混杂因素。
- 持续性作为疗效的替代指标,不能完全反映临床缓解或黏膜愈合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Medication persistence contributes real-world evidence about treatment effectiveness, tolerability and prescriber and patient acceptability. AIMS: To evaluate persistence of biological agents in Crohn's disease (CD) and ulcerative colitis (UC) and the effects of immunomodulator use and treatment lines. METHODS: Retrospective national population-based data on treatment persistence for adalimumab, infliximab vedolizumab and ustekinumab for CD and UC were analysed from the Australian Pharmaceutical Benefits Scheme using Kaplan-Meier analysis and Cox proportional hazards models. RESULTS: There were 2499 patients included with 8219 person-years of follow-up. In CD patients ustekinumab had increased persistence compared to anti-TNF agents (HR: 1.79, 95%CI: 1.32-2.38, P < 0.01). Twelve-month CD persistence rates were ustekinumab 80.0%, vedolizumab 73.5%, infliximab 68.1% and adalimumab 64.2% (P = 0.01). In moderate-severe UC vedolizumab had increased persistence compared to anti-TNF agents (HR: 1.67, 95% CI: 1.27-2.18 P < 0.001). Twelve-month UC persistence rates were vedolizumab 73.4%, infliximab 61.1% and adalimumab 45.5% (P < 0.001). Immunomodulator co-therapy did not significantly increase persistence in non-anti-TNF therapy (P > 0.05). Thiopurines increased persistence of anti-TNF agents in CD (P < 0.001) and UC (P = 0.03). Methotrexate co-therapy increased persistence of anti-TNF agents in CD (P = 0.001) only. First-line therapy was superior to non-first line in persistence (P < 0.001). In fistulising CD, the persistence of infliximab and adalimumab was not significantly different (P = 0.11). CONCLUSION: Persistence was highest in ustekinumab in CD and vedolizumab in UC. Factors which increased the persistence of biological agents are first-line therapy, and immunomodulator co-therapy in anti-TNF agent use.
引用
- Ko Y, Paramsothy S, Yau Y, et al. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Aliment Pharmacol Ther. 2021. PMID: 34151447. doi:10.1111/apt.16436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。